tiprankstipranks
Blurbs

BioNTech SE (BNTX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BioNTech SE (BNTXResearch Report), with a price target of $283.00. The company’s shares closed last Friday at $170.13, close to its 52-week low of $117.08.

According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -17.2% and a 29.4% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.

Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $224.40, implying a 35.6% upside from current levels. In a report issued on July 6, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $192.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $464.00 and a one-year low of $117.08. Currently, BioNTech SE has an average volume of 1.23M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed